Inhibikase Historical Income Statement

Stocks . USA . 
Stock . Inhibikase Therapeutics
IKT Stock  USD 2.34  0.03  1.30%   
Historical analysis of Inhibikase Therapeutics income statement accounts such as Selling General Administrative of 5.3 M or Total Revenue of 247.5 K can show how well Inhibikase Therapeutics performed in making a profits. Evaluating Inhibikase Therapeutics income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Inhibikase Therapeutics's future profits or losses.
Cash Flow   Balance Sheet     Income Statement
 
Covid
Financial Statement Analysis is much more than just reviewing and examining Inhibikase Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Inhibikase Therapeutics is a good buy for the upcoming year.
  
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Inhibikase Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in industry.
For more information on how to buy Inhibikase Stock please use our How to Invest in Inhibikase Therapeutics guide.

About Inhibikase Income Statement Analysis

Inhibikase Therapeutics Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Inhibikase Therapeutics shareholders. The income statement also shows Inhibikase investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Balance Sheet
Statement
Details
Cash Flow
Statement
Details
Financial
Indicators
Details
Valuation
Indicators
Details

Inhibikase Therapeutics Income Statement Chart

At this time, Inhibikase Therapeutics' Interest Expense is comparatively stable compared to the past year. Net Interest Income is likely to gain to about 935.8 K in 2024, whereas Selling General Administrative is likely to drop slightly above 5.3 M in 2024.
Interest Expense  Selling General Administrative  Total Revenue  Other Operating Expenses  Research Development  
Add Fundamental

Interest Expense

The cost incurred by an entity for borrowed funds, including loans, bonds, or lines of credit.

Total Revenue

Total revenue comprises all receipts Inhibikase Therapeutics generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Inhibikase Therapeutics. It is also known as Inhibikase Therapeutics overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.
Most accounts from Inhibikase Therapeutics' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Inhibikase Therapeutics current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Inhibikase Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in industry.
For more information on how to buy Inhibikase Stock please use our How to Invest in Inhibikase Therapeutics guide.At this time, Inhibikase Therapeutics' Interest Expense is comparatively stable compared to the past year. Net Interest Income is likely to gain to about 935.8 K in 2024, whereas Selling General Administrative is likely to drop slightly above 5.3 M in 2024.
 2021 2022 2023 2024 (projected)
Cost Of Revenue11.4M6.7K13.6M14.3M
Depreciation And Amortization14.8M6.7K177.4K168.5K

Inhibikase Therapeutics income statement Correlations

Ebit
Net Interest Income
Selling General Administrative
Total Revenue
Gross Profit
Other Operating Expenses
Operating Income
Net Income From Continuing Ops
Research Development
Ebitda
Total Operating Expenses
Income Before Tax
Total Other Income Expense Net
Net Income
Depreciation And Amortization
Cost Of Revenue
Income Tax Expense
Interest Income
Ebit
-0.76-0.960.80.8-0.961.01.0-0.91.0-0.831.0-0.751.00.34-0.730.88-0.69
Net Interest Income
-0.760.61-0.64-0.960.65-0.77-0.750.61-0.760.29-0.751.0-0.75-0.580.83-0.80.95
Selling General Administrative
-0.960.61-0.73-0.680.98-0.96-0.960.92-0.960.88-0.960.6-0.96-0.140.68-0.770.59
Total Revenue
0.8-0.64-0.730.8-0.740.780.77-0.530.78-0.620.77-0.630.770.61-0.410.77-0.57
Gross Profit
0.8-0.96-0.680.8-0.70.80.78-0.590.79-0.360.78-0.960.780.61-0.770.8-0.92
Other Operating Expenses
-0.960.650.98-0.74-0.7-0.97-0.970.96-0.970.85-0.970.64-0.97-0.270.64-0.850.65
Operating Income
1.0-0.77-0.960.780.8-0.971.0-0.921.0-0.831.0-0.761.00.34-0.740.9-0.7
Net Income From Continuing Ops
1.0-0.75-0.960.770.78-0.971.0-0.921.0-0.851.0-0.741.00.33-0.720.89-0.68
Research Development
-0.90.610.92-0.53-0.590.96-0.92-0.92-0.920.81-0.920.6-0.92-0.160.66-0.80.62
Ebitda
1.0-0.76-0.960.780.79-0.971.01.0-0.92-0.831.0-0.761.00.34-0.730.89-0.7
Total Operating Expenses
-0.830.290.88-0.62-0.360.85-0.83-0.850.81-0.83-0.850.28-0.85-0.050.37-0.670.19
Income Before Tax
1.0-0.75-0.960.770.78-0.971.01.0-0.921.0-0.85-0.741.00.33-0.720.89-0.68
Total Other Income Expense Net
-0.751.00.6-0.63-0.960.64-0.76-0.740.6-0.760.28-0.74-0.74-0.580.83-0.790.95
Net Income
1.0-0.75-0.960.770.78-0.971.01.0-0.921.0-0.851.0-0.740.33-0.720.89-0.68
Depreciation And Amortization
0.34-0.58-0.140.610.61-0.270.340.33-0.160.34-0.050.33-0.580.33-0.030.69-0.53
Cost Of Revenue
-0.730.830.68-0.41-0.770.64-0.74-0.720.66-0.730.37-0.720.83-0.72-0.03-0.520.8
Income Tax Expense
0.88-0.8-0.770.770.8-0.850.90.89-0.80.89-0.670.89-0.790.890.69-0.52-0.72
Interest Income
-0.690.950.59-0.57-0.920.65-0.7-0.680.62-0.70.19-0.680.95-0.68-0.530.8-0.72
Click cells to compare fundamentals

Inhibikase Therapeutics Account Relationship Matchups

High Positive Relationship

Operating Income
+ 1.0
Ebit
Net Income From Continuing Ops
+ 1.0
Ebit
Ebitda
+ 1.0
Ebit
Income Before Tax
+ 1.0
Ebit
Net Income
+ 1.0
Ebit
Total Other Income Expense Net
+ 1.0
Net Interest Income

High Negative Relationship

Net Income
- 0.97
Other Operating Expenses
Income Before Tax
- 0.97
Other Operating Expenses
Ebitda
- 0.97
Other Operating Expenses
Net Income From Continuing Ops
- 0.97
Other Operating Expenses
Operating Income
- 0.97
Other Operating Expenses
Total Other Income Expense Net
- 0.96
Gross Profit

Inhibikase Therapeutics income statement Accounts

201920202021202220232024 (projected)
Interest Expense24.8K29.4K19.9K74.5K85.6K89.9K
Net Income Applicable To Common Shares(2.2M)(5.7M)(2.8M)(14.8M)(13.3M)(12.6M)
Ebit(5.7M)(2.8M)(14.8M)(18.1M)(20.1M)(19.1M)
Net Interest Income(24.8K)(29.4K)(19.9K)74.5K891.2K935.8K
Selling General Administrative4.3M2.6M6.5M6.2M6.7M5.3M
Total Revenue1.1M698.5K3.1M123.4K260.5K247.5K
Gross Profit(1.4M)698.5K3.1M116.7K(13.4M)(12.7M)
Other Operating Expenses5.7M2.8M14.8M18.1M20.4M11.7M
Operating Income(5.7M)(2.8M)(14.8M)(18.1M)(20.1M)(19.1M)
Net Income From Continuing Ops(5.7M)(2.8M)(14.8M)(18.1M)(19.1M)(18.2M)
Research Development2.6M893.8K11.4M12.0M13.6M8.1M
Ebitda(5.7M)(2.8M)(14.8M)(18.1M)(19.9M)(18.9M)
Total Operating Expenses5.7M2.8M14.8M18.1M6.7M9.2M
Income Before Tax(5.7M)(2.8M)(14.8M)(18.1M)(19.0M)(18.1M)
Total Other Income Expense Net(24.8K)(29.4K)(19.9K)74.5K1.1M1.1M
Net Income(5.7M)(2.9M)(14.8M)(17.9M)(19.0M)(18.1M)

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Inhibikase Stock Analysis

When running Inhibikase Therapeutics' price analysis, check to measure Inhibikase Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Inhibikase Therapeutics is operating at the current time. Most of Inhibikase Therapeutics' value examination focuses on studying past and present price action to predict the probability of Inhibikase Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Inhibikase Therapeutics' price. Additionally, you may evaluate how the addition of Inhibikase Therapeutics to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY